Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

[1] Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A

prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012;27(12):1–5. doi: 10.1093/humrep/

des332.

[2] Taran FA, Weaver AL, Coddington CC, et al. Understanding adenomyosis: a case control study. Fertil Steril. 2010;94(4):1223–1228. doi:

10.1016/j.fertnstert.2009.06.049.

[3] Naftalin J, Hoo W, Pateman K, et al. Is adenomyosis associated with menorrhagia? Hum Reprod. 2014;29(3):473–479. doi: 10.1093/humrep/det451.

[4] García-Solares J, Donnez J, Donnez O, et al. Pathogenesis of uterine

adenomyosis: invagination or metaplasia? Fertil Steril. 2018;109(3):371–

379. doi: 10.1016/j.fertnstert.2017.12.030.

[5] Donnez J, Stratopoulou CA, Dolmans M-M. Uterine adenomyosis:

from disease pathogenesis to a new medical approach using GnRH

antagonists. Int J Environ Res Public Health. 2021;18:9941.

[6] Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the

management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.

doi: 10.1016/j.fertnstert.2018.01.013.

[7] Osuga Y, Hayashi K, Kanda S. Long-term use of dienogest for the

treatment of primary and secondary dysmenorrhea. J Obstet Gynaecol

Res. 2020;46(4):606–617. doi: 10.1111/jog.14209.

[8] Khan KN, Kitajima M, Hiraki K, et al. Cell proliferation effect of

GnRH agonist on pathological lesions of women with endometriosis,

adenomyosis and uterine myoma. Hum Reprod. 2010;25(11):2878–

2890. doi: 10.1093/humrep/deq240.

[9] Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in

premenopausal women with adenomyosis: a prospective clinical trial. Arch

Gynecol Obstet. 2015;292(6):1267–1271. doi: 10.1007/s00404-015-3755-5.

[10] Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors prevent the

estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists. Fertil Steril. 2009;91(4

Suppl):1574–1577. doi: 10.1016/j.fertnstert.2008.09.077.

[11] Osuga Y, Enya K, Kudou K, et al. Oral Gonadotropin-Releasing hormone antagonist relugolix compared with leuprorelin injections for

Gynecological Endocrinology

uterine leiomyomas: a randomized controlled trial. Obstet Gynecol.

2019;133(3):423–433. doi: 10.1097/AOG.0000000000003141.

[12] Taylor HS, Giudice LC, Lessey BA, et al. Treatment of

Endometriosis-Associated pain with elagolix, an oral GnRH antagonist.

N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089.

[13] Harada T, Osuga Y, Suzuki Y, et al. Relugolix, an oral gonadotropin-releasing

hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in japanese women: a phase 3, randomized,

double-blind, noninferiority study. Fertil Steril. 2022;117(3):583–592. doi:

10.1016/j.fertnstert.2021.11.013.

[14] Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist

(linzagolix): a new therapy for uterine adenomyosis. Fertil Steril.

2020;114(3):640–645. doi: 10.1016/j.fertnstert.2020.04.017.

[15] Bazot M, Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertil Steril.

2018;109(3):389–397. doi: 10.1016/j.fertnstert.2018.01.024.

[16] Munro MG. Classification and reporting systems for adenomyosis. J Minim

Invasive Gynecol. 2020;27(2):296–308. doi: 10.1016/j.jmig.2019.11.013.

[17] Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an

update on molecular mechanisms. Reprod Biomed Online. 2017;35(5):592–

601. doi: 10.1016/j.rbmo.2017.06.016.

[18] Bulun SE, Cheng Y-H, Yin P, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol.

2006;248(1-2):94–103. doi: 10.1016/j.mce.2005.11.041.

[19] Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum

Reprod Update. 2019;25(4):473–485. doi: 10.1093/humupd/dmz005.

[20] Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol.

2002;83(1-5):149–155. doi: 10.1016/s0960-0760(02)00260-1.

[21] Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation,

angiogenesis and apoptosis in endometriosis, adenomyosis and uterine

myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642–653.

doi: 10.1093/humrep/dep437.

[22] Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1355.

doi: 10.1056/NEJMra1209993.

[23] Matsushima T, Akira S, Yoneyama K, et al. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol. 2020;36(6):521–

524. doi: 10.1080/09513590.2019.1683818.

[24] Al-Hendy A, Lukes AS, Poindexter AN, 3rd, et al. Treatment of uterine

fibroid symptoms with relugolix combination therapy. N Engl J Med.

2021;384(7):630–642. doi: 10.1056/NEJMoa2008283.

...